Quantitative measurement of BCR/abl transcripts using real-time polymerase chain reaction

Annals of Oncology

Volumn 13, Issue 5, 2002, Pages 781-788

  Lee, W I ^a   Kantarjian, H ^a   Glassman, A ^a   Talpaz, M ^a   Lee, M S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chronic myelogenous leukemia; Interferon; Real time polymerase chain reaction; STI 571

Indexed keywords

BCR ABL PROTEIN; HYBRID PROTEIN; IMATINIB; INTERFERON; RNA;

ARTICLE; BONE MARROW; CASE CONTROL STUDY; CHRONIC MYELOID LEUKEMIA; COMPARATIVE STUDY; CULTURE TECHNIQUE; FEMALE; GENETIC TRANSCRIPTION; GENETICS; HUMAN; MALE; METHODOLOGY; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; ONCOGENE; PROBABILITY; REFERENCE VALUE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG RESPONSE; HUMAN CELL; KARYOTYPING; MAJOR CLINICAL STUDY; PATIENT MONITORING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TREATMENT OUTCOME;

BASE SEQUENCE; BONE MARROW; CASE-CONTROL STUDIES; CULTURE TECHNIQUES; FEMALE; FUSION PROTEINS, BCR-ABL; GENES, ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MALE; MOLECULAR SEQUENCE DATA; PROBABILITY; REFERENCE VALUES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TRANSCRIPTION, GENETIC; COMPARATIVE STUDY; HUMAN; SUPPORT, NON-U.S. GOV'T; TISSUE CULTURE;

EID: 0035985311     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf156     Document Type: Article

References (20)

1. A new consistent chromosome abnormality in chronic myelogenous leukemia
2. Cytogenetic analysis of hematologic malignant diseases
3. Fused transcript of abl and bcr genes in chronic myelogenous leukemia
4. Diagnosis of chronic myelogenous leukemia and acute leukemia by detection of leukemia-specific mRNA sequences amplified in vitro
5. Detection of two alternative bcr/abl mRNA junctions and minimal residual disease in Philadelphia chromosome positive chronic myelogenous leukemia by polymerase chain reaction
6. Detection of specific polymerase chain reaction product by utilizing the 5′ to 3′ exonuclease activity of thermus acquaticus DNA polymerase
7. Chronic myelogenous leukemia: Biology and therapy
8. Phase I trial of a specific abl tyrosine kinase inhibitor, CGP 57148, in interferon refractory chronic myelogenous leukemia patients
9. A phase II study of STI 571 in adult patients with Philadelphia chromosome positive chronic myeloid leukemia in accelerated phase
10. Phase II study of STI571, a tyrosine kinase inhibitor, in patients with resistant or refractory Philadelphia chromosome-positive chronic myeloid leukemia
11. Detection of minimal residual disease by polymerase chain reaction of bcr/abl transcripts in chronic myelogenous leukemia following allogeneic bone marrow transplantation
12. An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in hematologic disorders
13. Techniques in cancer cytogenetics: An overview and update
14. Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making?
15. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: Low level of minimal residual disease are associated with continuing remission
16. Persistence of bcr-abl genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-alpha therapy or allogeneic bone marrow transplantation
17. The amount of bcr-abl fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stage
18. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR
19. Detection and quantification of residual disease in chronic myelogenous leukemia
20. Treatment of Philadelphia chromosome positive early chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine